Immunotherapy of AML: future directions
Open Access
- 1 January 2000
- journal article
- review article
- Published by BMJ in Journal of Clinical Pathology
- Vol. 53 (1), 49-54
- https://doi.org/10.1136/jcp.53.1.49
Abstract
Immunotherapy in the form of allogeneic GvL has been curing AML patients for nearly 30 years but our understanding of the mechanisms has been poor. Our rapidly evolving understanding of the human immune system and the concomitant technical developments in ex vivo cell manipulation, the vision of funding bodies, the dedication of clinical and research staff, and above all the commitment of our patients, promise substantial progress in the treatment of this disease in the year 2000 and beyond.Keywords
This publication has 60 references indexed in Scilit:
- Treatment of acute myeloid leukaemia patients with recombinant interleukin 2: a pilot studyBritish Journal of Haematology, 2008
- Selective removal of alloreactive cells from haematopoietic stem cell grafts: graft engineering for GVHD prophylaxisBone Marrow Transplantation, 1999
- Enhanced immune costimulatory activity of primary acute myeloid leukaemia blasts after retrovirus-mediated gene transfer of B7.1Gene Therapy, 1997
- Construction and Biological Characterization of an Interleukin-12 Fusion Protein (Flexi-12): Delivery to Acute Myeloid Leukemic Blasts Using Adeno-Associated VirusHuman Gene Therapy, 1997
- The in vitro detection of anti-leukaemia-specific cytotoxicity after autologous bone marrow transplantation for acute leukaemiaBone Marrow Transplantation, 1997
- Generation of dendritic cells expressing bcr-abl from CD34-positive chronic myeloid leukemia precursor cellsHuman Immunology, 1997
- Interleukin 12 synergizes with B7/CD28 interaction in inducing efficient proliferation and cytokine production of human T cells.The Journal of Experimental Medicine, 1994
- Generation of Donor-Derived Antileukemic Cytotoxic T-Lymphocyte Responses for Treatment of Relapsed Leukemia After Allogeneic HLA-Identical Bone Marrow TransplantationJournal of Immunotherapy, 1993
- Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells.The Journal of Experimental Medicine, 1993
- Treatment of Murine Leukaemia with X Rays and Homologous Bone MarrowBMJ, 1956